Leishmania major causes cutaneous leishmaniasis with the primary challenges in treatment include the emergence of resistance, prolonged treatment duration, high costs associated with current medications and their toxicity. Additionally, the intracellular nature of the parasite hinders drug access, as the drug needs to cross the host cell membrane and the phagolysosome, making its effect more difficult. While the therapeutic effects of fluconazole on leishmaniasis have been explored in several studies, its low bioavailability and solubility should be circumvented by new and targeted carriers without these issues. In this study, fluconazole was encapsulated within mannosylated-albumin nanoparticles (NPs) for selective delivery to the host macrophages for the treatment of Leishmania major. Both targeted and non-targeted carriers were synthesized and characterized by measurements on zeta (z) potential, particle size, mannosylation level, fluconazole entrapment efficiency and loading capacity, uptake level by the macrophages, and fluconazole release rate. In vitro cytotoxicity against macrophages, promastigotes and amastigotes was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and the results were compared with free fluconazole and glucantime (meglumine antimoniate). IC50 for glucantime, fluconazole, fluconazole-albumin NPs, and targeted fluconazole-albumin NPs against the Leishmania major promastigotes after 48 hours were obtained as 180.3 ± 8.8, 134.7 ± 9.1, 105.6 ± 11.1, and 62.2 ± 10.4 μg mL-1, respectively. Treatment of Leishmania major amastigotes using glucantime, fluconazole, fluconazole-albumin NPs, and targeted fluconazole-albumin NPs had IC50 of 122.9 ± 11.3, 101.2 ± 9.5, 71.6 ± 5.1, and 28.0 ± 3.3 μg mL-1, respectively. In addition, targeted fluconazole-albumin NPs represented high values of selectivity toward the parasite promastigotes as well as amastigotes, compared to the host cells.